Company Number: 14184252

Analysis Date: 2025-07-29 15:54 UTC

1. Risk Rating: HIGH
   Justification: The company exhibits net liabilities and negative shareholder funds as of the latest financial year. Significant long-term liabilities (£40,000) with limited current assets and no employees indicate potential solvency and operational sustainability concerns.

2. Key Concerns:

• Negative net assets of £4,680 as of 30 June 2024, indicating insolvency on a balance sheet basis.
• Presence of £40,000 creditors due after more than one year, a material long-term liability relative to company size.
• Zero employees and lack of profit and loss account filing may suggest limited operational activity and reduced transparency.

3. Positive Indicators:

• Company status is active with no overdue filings for accounts or confirmation statements, demonstrating regulatory compliance and good governance discipline.
• Incremental increase in fixed assets from £0 to £18,600 suggests some investment in tangible or intangible resources.
• Micro-entity reporting exemptions are properly applied, reducing administrative burden.

4. Due Diligence Notes:

• Investigate nature, terms, and repayment schedule of the £40,000 long-term creditor to assess refinancing or default risk.
• Clarify absence of employees and review business model viability and revenue streams, given the industry classifications (market research, biotech R&D, technical testing, management consultancy).
• Review underlying causes of accumulated losses leading to negative equity and confirm if director or shareholder loans are included in liabilities.
• Obtain profit and loss accounts for a complete understanding of income, expenses, and cash flow dynamics.
• Confirm director’s plans or external funding arrangements intended to restore positive net asset position and operational sustainability.